יחס מהיר Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) generates revenue based on the implementation of innovative immunotherapy to combat tumors and infections. The price indicator on the chart, with a value of 1.19, confirms the asset's market dynamics. Cue Biopharma, Inc. (CUE) holds patents for the selective stimulation of T-lymphocytes, which will ensure future licensing payments. The business is currently expanding the scope of clinical trials, seeking to attract major partners for the commercial utilization of its molecules.

Quick liquidity determines the ability of Cue Biopharma, Inc. (CUE) to meet short-term obligations using cash and accounts receivable, completely excluding illiquid inventories from the calculation. By analyzing the quick ratio on GURU.Markets, an investor can see the real margin of safety for Cue Biopharma, Inc. (CUE), which is critically important given the current optimization of R&D expenses to extend the operational development cycle of immunotherapy.